Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a 15th CMHC Annual meeting session, will cover a concise overview of the efficacy and safety of metabolic surgery in reducing cardiometabolic risk across BMI levels.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD compared to patients with these conditions and no concomitant diabetes.  As such, current antiplatelet therapy to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting. 
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Current evidence supports post-prandial glucose (PPG) control as an important strategy to consider in the comprehensive management plan of individuals with diabetes.  However, managing PPG remains one of the most challenging aspects of diabetes care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
While a substantial body of research demonstrates the need to address the global epidemic of metabolic syndrome, and the constellation of associated cardiometabolic risk factors simultaneously, the majority of them are still treated as separate entities.The engaging and interactive session recordings from this Masterclass cover experts across specialties on the current state of affairs and advances in cardiometabolic disease including team based-care, telemedicine, cardio-renal risk reduction, obesity management, and much more.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases NAFLD and NASH, which are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is poised to become the leading cause of liver transplants in the US.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in atopic dermatitis presented at the 29th Annual Masters of Pediatric Dermatology and the 19th Annual South Beach Symposium.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in psoriasis presented at the 29th Annual Masters of Pediatric Dermatology and the 19th Annual South Beach Symposium.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Acne is a chronic and inflammatory skin disorder that affects up to 50 million individuals in the United States and is one of the most common dermatologic conditions in children and adolescents (Lim 2017; Nagler 2016). Acne is characterized by noninflammatory lesions (open and closed comedones) and inflammatory lesions (papules, pustules, and nodules). The pathogenic mechanisms include microbial colonization with Propionibacterium acnes (P acnes), sebum production, inflammatory mechanisms, and follicular hyperkeratinization (Eichenfield 2013).

Pages